The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes.
Adolescent
Adult
Aged
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
COVID-19
/ epidemiology
COVID-19 Vaccines
/ therapeutic use
Cohort Studies
Diabetes Mellitus, Type 1
/ blood
Female
Glycated Hemoglobin
/ analysis
Glycemic Control
/ methods
Humans
Male
Middle Aged
Treatment Outcome
United Kingdom
/ epidemiology
Vaccination
/ methods
Young Adult
COVID-19 vaccination
HbA1c
flash glucose monitoring
glycaemic stability
type 1 diabetes
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
02
06
2021
accepted:
20
12
2021
pubmed:
23
12
2021
medline:
25
3
2022
entrez:
22
12
2021
Statut:
ppublish
Résumé
Evidence suggests that some people with type 1 diabetes mellitus (T1DM) experience temporary instability of blood glucose (BG) levels after COVID-19 vaccination. We aimed to assess this objectively. We examined the interstitial glucose profile of 97 consecutive adults (age ≥ 18 years) with T1DM using the FreeStyle Libre There was a significant decrease in the % interstitial glucose on target (3.9-10.0) for the 7 days following vaccination (mean 52.2% ± 2.0%) versus pre-COVID-19 vaccination (mean 55.0% ± 2.0%) (p = 0.030). 58% of individuals with T1DM showed a reduction in the 'time in target range' in the week after vaccination. 30% showed a decrease of time within the target range of over 10%, and 10% showed a decrease in time within target range of over 20%. The change in interstitial glucose proportion on target in the week following vaccination was most pronounced for people taking metformin/dapagliflozin + basal bolus insulin (change -7.6%) and for people with HbA In T1DM, we have shown that initial COVID-19 vaccination can cause temporary perturbation of interstitial glucose, with this effect more pronounced in people talking oral hypoglycaemic medication plus insulin, and when HbA
Substances chimiques
Blood Glucose
0
COVID-19 Vaccines
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14774Informations de copyright
© 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Rawaf S, Allen LN, Stigler FL, et al. Lessons on the COVID-19 pandemic, for and by primary care professionals worldwide. Eur J Gen Pract. 2020;26:129-133.
Krist AH, DeVoe JE, Cheng A, Ehrlich T, Jones SM. Redesigning primary care to address the COVID-19 pandemic in the midst of the pandemic. Ann Fam Med. 2020;18:349-354.
Tian Z, Heald AH, Stedman M, et al. Age of people with Type 2 diabetes and the risk of dying following SARS-CoV-2 infection. IJCP in press 2021.
Riddle MC, Buse JB, Franks PW, et al. COVID-19 in people with diabetes: urgently needed lessons from early reports. Diabetes Care. 2020;43:1378-1381.
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.
Kalra S. Gupta Y ambulatory glucose profile: flash glucose monitoring. J Pak Med Assoc. 2015;65:1360-1362.
Yadegarfar G, Anderson SG, Khawaja Z, et al. The FreeStyle Libre flash glucose monitoring system: how it has improved glycaemic control for people with type 1 diabetes in Eastern Cheshire, UK. Cardiovasc Endocrinol Metab. 2020;9(4):171-176.
Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Maciejewska I, Szutowicz A, Pawelczyk T. High glucose concentration impairs ATP outflow and immunoglobulin production by human peripheral B lymphocytes: involvement of P2X7 receptor. Immunobiol. 2013;218:591-601.
Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes. 1990;39:271-275.
https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine Accessed 19 April 2021
https://www.libreview.com Accessed 19 April 2021
https://www.nice.org.uk/guidance/NG17 Last updated July 2016 Accessed 22 March 2020
Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges. Diabetes Metab Syndr. 2021;15:505-508.
Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
Yadegarfar G, Livingston M, Cortes G, et al. Dapagliflozin: an effective adjunctive treatment in type 1 diabetes. Cardiovasc Endocrinol Metab. 2021;10:132-136.
Voysey M, Clemens SAC, Madhi SA, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;9:99-111.
Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.
www.gov.uk/government/publications/priority-groups-for-phase-2-of-the-coronavirus-covid-19-vaccination-programme-advice-from-the-jcvi/jcvi-final-statement-on-phase-2-of-the-covid-19-vaccination-programme-13-april-2021 Accessed 15 October 2021
Glaess SS, Benitez RM, Cross BM, Urteaga EM. Acute hyperglycemia after influenza vaccination in a patient with type 2 diabetes. Diabetes Spectr. 2018;31:206-208.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/970504/COVID-19_mRNA_Pfizer-_BioNTech_Vaccine_Analysis_Print.pdf Accessed 20 April 2021
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/970505/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf Accessed 20 March 2021
Mishra A, Ghosh A, Dutta K, Tyagi K, Misra A. Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: report of three cases. Diabetes Metab Syndr. 2021;15:102151.
Mifsud S, Schembri EL, Gruppetta M. Stress-induced hyperglycaemia. Br J Hosp Med (Lond). 2018;79:634-663.
Galassetti P, Tate D, Neill RA, Morrey S, Wasserman DH, Davis SN. Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes. 2003;52:1761-1769.
Wise J. Covid-19: people who have had infection might only need one dose of mRNA vaccine. BMJ. 2021;372:n308. doi: 10.1136/bmj.n308
Šestan M, Marinović S, Kavazović I, et al. Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity. 2018;49:164-177.e6.
Shi J, Fan J, Su Q, Yang Z. Cytokines and abnormal glucose and lipid metabolism. Front Endocrinol. 2019;10:703.